RxDoctor Payments Data

Derek Korte, DO

Gastroenterology · Grand Blanc, MINPI 1346226495

Payments from drug & device makers

$3,499in general payments, 2019–2025

Across 136 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$362
  • Takeda Pharmaceuticals U.S.A., Inc.$324
  • Intercept Pharmaceuticals, Inc.$319
  • Ardelyx, Inc.$195
  • Gilead$169
  • plus $911 from 13 others

What the payments were for

  • Food & beverage$3,47699%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,499 in reported general payments places this provider in the 55th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$72,551
Medicare patients
380
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin29$113,081
Humira PenAdalimumab15$99,632
LinzessLinaclotide24$27,640
Mesalamine41$24,481
Mesalamine DrMesalamine12$10,381
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg291$8,371
Balsalazide Disodium16$4,616
Ursodiol20$4,457
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates50$3,378
Pantoprazole Sodium123$2,541
Azathioprine29$1,640
Budesonide EcBudesonide11$1,606
Colestipol Hcl29$1,591
Omeprazole68$1,290
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl60$1,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$108$113,08129 claims
AbbVieLinzess$1,218$27,64024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →